Calcitonin Salmon

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity Reactions, including anaphylaxis [see Warnings and Precautions (5.1)] Hypocalcemia [see Warnings and Precautions (5.2)] Nasal Adverse Reactions [see Warnings and Precautions (5.3)] Malignancy [see Warnings and Precautions (5.4)] Most common adverse reactions (3% or greater) are rhinitis, epistaxis and other nasal symptoms, back pain, arthralgia, and headache ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of calcitonin salmon nasal spray in the treatment of postmenopausal osteoporosis was assessed in 5 randomized, double-blind, placebo controlled trials that enrolled postmenopausal women, aged 45 to 75 years. The duration of the trials ranged from 1 to 2 years. The incidence of adverse reactions reported in studies involving postmenopausal osteoporotic patients chronically exposed to calcitonin salmon nasal spray (N=341) and to placebo nasal spray (N=131), and reported in greater than 3% of calcitonin salmon nasal spray treated patients are presented in the following table. Other than flushing, nausea, possible allergic reactions, and possible local irritative effects in the respiratory tract, a relationship to calcitonin salmon nasal spray has not been established. Table 1: Adverse Reactions Occurring in at Least 3% of Postmenopausal Patients Treated with Calcitonin Salmon Nasal Spray †Symptom of nose includes: nasal crusts, dryness, redness or erythema, nasal sores, irritation, itching, thick feeling, soreness, pallor, infection, stenosis, runny/blocked, small wound, bleeding wound, tenderness, uncomfortable feeling and sore across bridge of nose. Calcitonin Salmon Nasal Spray Placebo Nasal Spray Adverse Reaction N=341 % of Patients N=131 % of Patients Rhinitis 12 7 Symptom of Nose† 11 16 Back Pain 5 2 Arthralgia 4 5 Epistaxis 4 5 Headache 3 5 Nasal Adverse Reactions In all postmenopausal patients treated with calcitonin salmon nasal spray, the most commonly reported nasal adverse reactions included rhinitis (12%), epistaxis (4%), and sinusitis (2%). Smoking did not have a contributory effect on the occurrence of nasal adverse reactions. Adverse reactions reported in 1% to 3% of patients treated with calcitonin salmon nasal spray include: influenza-like symptoms, erythematous rash, arthrosis, myalgia, sinusitis, upper respiratory tract infection, bronchospasm, abdominal pain, nausea, dizziness, paresthesia, abnormal lacrimation, conjunctivitis, lymphadenopathy, infection, and depression. Malignancy A meta-analysis of 21 randomized, controlled clinical trials with calcitonin salmon (nasal spray or investigational oral formulations) was conducted to assess the risk of malignancies in calcitonin salmon-treated patients compared to placebo-treated patients. The trials in the meta-analysis ranged in duration from 6 months to 5 years and included a total of 10883 patients (6151 treated with calcitonin salmon and 4732 treated with placebo). The overall incidence of malignancies reported in these 21 trials was higher among calcitonin salmon-treated patients (254/6151 or 4.1%) compared with placebo-treated patients (137/4732 or 2.9%). Findings were similar when analyses were restricted to the 18 nasal spray only trials [calcitonin salmon 122/2712 (4.5%); placebo 30/1309 (2.3%)]. The meta-analysis results suggest an increased risk of overall malignancies in calcitonin salmon-treated patients compared to placebo-treated patients when all 21 trials are included and when the analysis is restricted to the 18 nasal spray only trials (see Table 2). It is not possible to exclude an increased risk when calcitonin salmon is administered by the subcutaneous, intramuscular, or intravenous route because these routes of administration were not investigated in the meta-analysis. The increased malignancy risk seen with the meta-analysis was heavily influenced by a single large 5-year trial, which had an observed risk difference of 3.4% [95% CI (0.4%, 6.5%)]. Imbalances in risks were still observed when analyses excluded basal cell carcinoma (see Table 2); the data were not sufficient for further analyses by type of malignancy. A mechanism for these observations has not been identified. Although a definitive causal relationship between calcitonin salmon use and malignancies cannot be established from this meta-analysis, the benefits for the individual patient should be carefully evaluated against all possible risks [see Warnings and Precautions (5.4)] . Table 2: Risk Difference for Malignancies in Calcitonin Salmon-Treated Patients Compared with Placebo-Treated Patients 1 The overall adjusted risk difference is the difference between the percentage of patients who had any malignancy (or malignancy excluding basal cell carcinoma) in calcitonin salmon and placebo treatment groups, using the Mantel-Haenszel (MH) fixed-effect method. A risk difference of 0 is suggestive of no difference in malignancy risks between the treatment groups. 2 The corresponding 95% confidence interval for the overall adjusted risk difference also based on MH fixed-effect method. Patients Malignancies Risk Difference 1 (%) 95% Confidence Interval 2 (%) All (nasal spray + oral) All 1.0 (0.3, 1.6) All (nasal spray + oral) Excluding basal cell carcinoma 0.5 (-0.1, 1.2) All (nasal spray only) All 1.4 (0.3, 2.6) All (nasal spray only) Excluding basal cell carcinoma 0.8 (-0.2, 1.8) 6.2 Postmarketing Experience Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported during post-approval use of calcitonin salmon nasal spray. Allergic / Hypersensitivity Reactions Serious allergic reactions have been reported in patients receiving calcitonin salmon nasal spray, including anaphylaxis and anaphylactic shock. Hypocalcemia Hypocalcemia with paresthesia has been reported. Body as a whole facial or peripheral edema Cardiovascular hypertension, vasodilatation, syncope, chest pain Nervous system dizziness, seizure, visual or hearing impairment, tinnitus Respiratory/Special Senses cough, bronchospasm, dyspnea, loss of taste/smell Skin rash/dermatitis, pruritus, alopecia, increased sweating Gastrointestinal diarrhea Nervous system disorders tremor 6.3 Immunogenicity Consistent with the potentially immunogenic properties of medicinal products containing peptides, administration of calcitonin salmon nasal spray may trigger the development of anti-calcitonin antibodies. In a two-year calcitonin salmon nasal spray clinical study that evaluated immunogenicity, a measurable antibody titer was found in 69% of patients treated with calcitonin salmon nasal spray and 3% of placebo-treated patients. Antibody formation may be associated with a loss of response to treatment [see Warnings and Precautions (5.5)] . The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of a positive antibody test result may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of antibodies to calcitonin salmon nasal spray with the incidence of antibodies to other calcitonin-containing products may be misleading.

4 CONTRAINDICATIONS Hypersensitivity to calcitonin salmon or any of the excipients. Reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see Warnings and Precautions (5.1)] . Hypersensitivity to calcitonin salmon or any of the excipients ( 4 )

11 DESCRIPTION Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. Calcitonin Salmon (synthetic origin) Nasal Spray is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin. This is shown by the following graphic formula: It is provided in a 2 mL or 3.7 mL fill glass bottle as a solution for nasal administration. This is sufficient medication for at least 14 doses (2 mL fill) or 30 doses (3.7 mL fill). Active Ingredient : calcitonin salmon 2200 USP Calcitonin Salmon Units per mL (corresponding to 200 USP Calcitonin Salmon Units per 0.09 mL actuation). Inactive Ingredients : benzalkonium chloride, hydrochloric acid (added as necessary to adjust pH), purified water and sodium chloride. The activity of calcitonin salmon nasal spray is stated in International Units based on bioassay in comparison with the International Reference Preparation of calcitonin salmon for Bioassay, distributed by the National Institute of Biological Standards and Control, Holly Hill, London.

2 DOSAGE AND ADMINISTRATION For intranasal use only: one spray (200 USP Calcitonin Salmon Units) per day, alternating nostrils daily ( 2.1 ) Prior to first use, allow the bottle to reach room temperature and prime the pump ( 2.2 ) Ensure adequate calcium and vitamin D intake ( 2.3 ) 2.1 Basic Dosing Information The recommended dose of calcitonin salmon nasal spray is 1 spray (200 USP Calcitonin Salmon Units) per day administered intranasally, alternating nostrils daily. 2.2 Priming (Activation) of Pump Unopened calcitonin salmon nasal spray should be stored in the refrigerator. Before using the first dose of calcitonin salmon nasal spray, the patient should wait until it has reached room temperature. To prime the pump before it is used for the first time, the bottle should be held upright and the two white side arms of the pump depressed toward the bottle, repeat until a full spray is released. The pump is primed once the first full spray is emitted. To administer, the nozzle should first be carefully placed into the nostril while the patient’s head is in the upright position, then the pump should be firmly depressed toward the bottle. The pump should not be primed before each daily dose. 2.3 Recommendations for Calcium and Vitamin D Supplementation Patients who use calcitonin salmon nasal spray should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).

1 INDICATIONS AND USAGE Calcitonin Salmon (synthetic origin) Nasal Spray is a calcitonin, indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.1 ) Limitations of Use: Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.2 , 5.4 ) Calcitonin salmon nasal spray has not been shown to increase bone mineral density in early postmenopausal women ( 1.2 ) 1.1 Treatment of Postmenopausal Osteoporosis Calcitonin Salmon (synthetic origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. Fracture reduction efficacy has not been demonstrated. Calcitonin Salmon (synthetic origin) Nasal Spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.2 Important Limitations of Use Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see Warnings and Precautions (5.4)] . Calcitonin Salmon (synthetic origin) Nasal Spray has not been shown to increase spinal bone mineral density in early postmenopausal women.

10 OVERDOSAGE The pharmacologic actions of calcitonin salmon nasal spray suggest that hypocalcemic tetany could occur in overdose. Therefore, provisions for parenteral administration of calcium should be available for the treatment of overdose. Single doses of calcitonin salmon nasal spray up to 1600 International Units, doses up to 800 International Units per day for 3 days and chronic administration of doses up to 600 International Units per day have been studied without serious adverse effects.

7 DRUG INTERACTIONS No formal drug interaction studies have been performed with calcitonin salmon nasal spray. Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment. Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment ( 7 )

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts. 12.2 Pharmacodynamics The information below, describing the clinical pharmacology of calcitonin, has been derived from studies with injectable calcitonin salmon. The mean bioavailability of calcitonin salmon nasal spray is approximately 3% of the injectable calcitonin salmon in healthy subjects and, therefore, the conclusions concerning the clinical pharmacology of this preparation may be different. Bone Single injections of calcitonin salmon caused a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In healthy adults, who have a relatively low rate of bone resorption, the administration of exogenous calcitonin salmon results in decreases in serum calcium within the limits of the normal range. In healthy children and in patients whose bone resorption is more rapid, decreases in serum calcium are more pronounced in response to calcitonin salmon. Kidney Studies with injectable calcitonin salmon show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption. Comparable studies have not been conducted with calcitonin salmon nasal spray. Gastrointestinal Tract Some evidence from studies with injectable preparations suggests that calcitonin salmon may have effects on the gastrointestinal tract. Short-term administration of injectable calcitonin salmon results in marked transient decreases in the volume and acidity of gastric juice and in the volume and the trypsin and amylase content of pancreatic juice. Whether these effects continue to be elicited after each injection of calcitonin salmon during chronic therapy has not been investigated. These studies have not been conducted with calcitonin salmon nasal spray. Calcium Homeostasis In two clinical studies designed to evaluate the pharmacodynamic response to calcitonin salmon nasal spray, administration of calcitonin salmon 100 to 1600 International Units to healthy volunteers resulted in rapid and sustained decreases within the normal range for both total serum calcium and serum ionized calcium. Single doses of calcitonin salmon greater than 400 International Units did not produce any further biological response to the drug. 12.3 Pharmacokinetics The bioavailability of calcitonin salmon nasal spray relative to intramuscular administration in healthy volunteers is between 3% and 5%. Calcitonin salmon nasal spray is absorbed rapidly by the nasal mucosa with a mean T max of about 13 minutes. The terminal half-life of calcitonin salmon has been calculated to be around 18 minutes and no evidence of accumulation was observed with multiple dosing.

12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.

12.2 Pharmacodynamics The information below, describing the clinical pharmacology of calcitonin, has been derived from studies with injectable calcitonin salmon. The mean bioavailability of calcitonin salmon nasal spray is approximately 3% of the injectable calcitonin salmon in healthy subjects and, therefore, the conclusions concerning the clinical pharmacology of this preparation may be different. Bone Single injections of calcitonin salmon caused a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In healthy adults, who have a relatively low rate of bone resorption, the administration of exogenous calcitonin salmon results in decreases in serum calcium within the limits of the normal range. In healthy children and in patients whose bone resorption is more rapid, decreases in serum calcium are more pronounced in response to calcitonin salmon. Kidney Studies with injectable calcitonin salmon show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption. Comparable studies have not been conducted with calcitonin salmon nasal spray. Gastrointestinal Tract Some evidence from studies with injectable preparations suggests that calcitonin salmon may have effects on the gastrointestinal tract. Short-term administration of injectable calcitonin salmon results in marked transient decreases in the volume and acidity of gastric juice and in the volume and the trypsin and amylase content of pancreatic juice. Whether these effects continue to be elicited after each injection of calcitonin salmon during chronic therapy has not been investigated. These studies have not been conducted with calcitonin salmon nasal spray. Calcium Homeostasis In two clinical studies designed to evaluate the pharmacodynamic response to calcitonin salmon nasal spray, administration of calcitonin salmon 100 to 1600 International Units to healthy volunteers resulted in rapid and sustained decreases within the normal range for both total serum calcium and serum ionized calcium. Single doses of calcitonin salmon greater than 400 International Units did not produce any further biological response to the drug.

12.3 Pharmacokinetics The bioavailability of calcitonin salmon nasal spray relative to intramuscular administration in healthy volunteers is between 3% and 5%. Calcitonin salmon nasal spray is absorbed rapidly by the nasal mucosa with a mean T max of about 13 minutes. The terminal half-life of calcitonin salmon has been calculated to be around 18 minutes and no evidence of accumulation was observed with multiple dosing.

20230918

100

3 DOSAGE FORMS AND STRENGTHS Calcitonin Salmon (synthetic origin) Nasal Spray consists of one glass bottle with attached pump. The bottle contains 2 mL or 3.7 mL of calcitonin salmon clear solution at a concentration of 2200 USP Calcitonin Salmon Units per mL. A primed pump delivers 0.09 mL (200 USP Calcitonin Salmon Units) calcitonin salmon per actuation. Nasal Spray: 2200 USP Calcitonin Salmon Units per mL of calcitonin salmon in a 2 mL or 3.7 mL fill glass bottle with attached pump. Each actuation delivers 200 USP Calcitonin Salmon Units of calcitonin salmon ( 3 )

Calcitonin Salmon Calcitonin Salmon CALCITONIN SALMON CALCITONIN SALMON BENZALKONIUM CHLORIDE HYDROCHLORIC ACID WATER SODIUM CHLORIDE graphic-formula Figure-01 Figure-02 Figure-03 Figure-04 Figure-05 Figure-06

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity The incidence of pituitary adenomas was increased in rats after one and two years of subcutaneous exposure to synthetic calcitonin salmon. The significance of this finding to humans is unknown because pituitary adenomas are very common in rats as they age, the pituitary adenomas did not transform into metastatic tumors, there were no other clear treatment-related neoplasms, and synthetic calcitonin salmon related neoplasms were not observed in mice after two years of dosing. Rat findings The only clear neoplastic finding in rats dosed subcutaneously with synthetic calcitonin salmon was an increase in the incidence of pituitary adenomas in male Fisher 344 rats and female Sprague Dawley rats after one year of dosing and male Sprague Dawley rats dosed for one and two years. In female Sprague Dawley rats, the incidence of pituitary adenomas after two years was high in all treatment groups (between 80% and 92% including the control groups) such that a treatment-related effect could not be distinguished from natural background incidence. The lowest dose in male Sprague Dawley rats that developed an increased incidence of pituitary adenomas after two years of dosing (1.7 International Units/kg/day) is approximately 2 times the maximum recommended intranasal dose in humans (200 International Units/day) based on body surface area conversion between rats and humans and a 20-fold conversion factor to account for decreased clinical exposure via the intranasal route. The findings suggest that calcitonin salmon reduced the latency period for development of non-functioning pituitary adenomas. Mouse findings No carcinogenicity potential was evident in male or female mice dosed subcutaneously for two years with synthetic calcitonin salmon at doses up to 800 International Units/kg/day. The 800 International Units/kg/day dose is approximately 390 times the maximum recommended intranasal dose in humans (200 International Units) based on scaling for body surface area and a 20-fold conversion factor to account for low clinical exposure via the intranasal route. Mutagenesis Synthetic calcitonin salmon tested negative for mutagenicity using Salmonella typhimurium (5 strains) and Escherichia coli (2 strains), with and without rat liver metabolic activation, and was not clastogenic in a chromosome aberration test in Chinese Hamster V79 cells. There was no evidence that calcitonin salmon was clastogenic in the in vivo mouse micronucleus test. Fertility Effects of calcitonin salmon on fertility have not been assessed in animals.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity The incidence of pituitary adenomas was increased in rats after one and two years of subcutaneous exposure to synthetic calcitonin salmon. The significance of this finding to humans is unknown because pituitary adenomas are very common in rats as they age, the pituitary adenomas did not transform into metastatic tumors, there were no other clear treatment-related neoplasms, and synthetic calcitonin salmon related neoplasms were not observed in mice after two years of dosing. Rat findings The only clear neoplastic finding in rats dosed subcutaneously with synthetic calcitonin salmon was an increase in the incidence of pituitary adenomas in male Fisher 344 rats and female Sprague Dawley rats after one year of dosing and male Sprague Dawley rats dosed for one and two years. In female Sprague Dawley rats, the incidence of pituitary adenomas after two years was high in all treatment groups (between 80% and 92% including the control groups) such that a treatment-related effect could not be distinguished from natural background incidence. The lowest dose in male Sprague Dawley rats that developed an increased incidence of pituitary adenomas after two years of dosing (1.7 International Units/kg/day) is approximately 2 times the maximum recommended intranasal dose in humans (200 International Units/day) based on body surface area conversion between rats and humans and a 20-fold conversion factor to account for decreased clinical exposure via the intranasal route. The findings suggest that calcitonin salmon reduced the latency period for development of non-functioning pituitary adenomas. Mouse findings No carcinogenicity potential was evident in male or female mice dosed subcutaneously for two years with synthetic calcitonin salmon at doses up to 800 International Units/kg/day. The 800 International Units/kg/day dose is approximately 390 times the maximum recommended intranasal dose in humans (200 International Units) based on scaling for body surface area and a 20-fold conversion factor to account for low clinical exposure via the intranasal route. Mutagenesis Synthetic calcitonin salmon tested negative for mutagenicity using Salmonella typhimurium (5 strains) and Escherichia coli (2 strains), with and without rat liver metabolic activation, and was not clastogenic in a chromosome aberration test in Chinese Hamster V79 cells. There was no evidence that calcitonin salmon was clastogenic in the in vivo mouse micronucleus test. Fertility Effects of calcitonin salmon on fertility have not been assessed in animals.

ANDA076396

Calcitonin Salmon

Calcitonin Salmon

72162-2128

HUMAN PRESCRIPTION DRUG

NASAL

Calcitonin Salmon 200 [iu] Spray #3.7mL Label

INSTRUCTIONS FOR USE Calcitonin Salmon (synthetic origin) (kal" si toe' nin) Nasal Spray For Nasal Use Only. Important information about your Calcitonin Salmon (synthetic origin) Nasal Spray: A single spray of Calcitonin Salmon (synthetic origin) Nasal Spray contains 1 daily dose of medicine. Each Calcitonin Salmon (synthetic origin) Nasal Spray bottle contains the right amount of medicine. The bottle may not be completely filled to the top. This is normal. This package contains 1 bottle of Calcitonin Salmon (synthetic origin) Nasal Spray with attached pump. Store unopened bottles of Calcitonin Salmon (synthetic origin) Nasal Spray in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. After you open your bottle of Calcitonin Salmon (synthetic origin) Nasal Spray, store it at room temperature between 20°C to 25°C (68°F to 77°F) in an upright position. Do not shake the bottle. Preparing your Calcitonin Salmon (synthetic origin) Nasal Spray: Step 1. Remove the bottle from your refrigerator and let it reach room temperature. Check the medicine in the bottle to make sure it is clear and colorless without particles. Step 2. Remove the clear plastic dust cap and the blue safety clip from the nasal spray pump. See Figure 1 . The safety clip prevents the accidental discharge of the spray in your pocket or purse. Step 3. Check to see if your Calcitonin Salmon (synthetic origin) Nasal Spray has been primed. To make sure you get the right dose of Calcitonin Salmon (synthetic origin) Nasal Spray medicine you must prime each new bottle and pump before you use it for the first time. Check to see if the bottle and pump has already been primed by pressing on the pump 1 time. See Figure 2. If you see a full spray from the pump, the bottle and pump has already been primed for you. If you do not see a full spray, you must prime the bottle and pump. Step 4. Priming your Calcitonin Salmon (synthetic origin) Nasal Spray: Hold the bottle upright with your pointer finger and middle finger on the 2 side arms of the pump, and your thumb on the bottom of the bottle. Firmly press down on the arms of the pump and press down again if needed until you see a full spray of medicine. See Figure 2. Now your Calcitonin Salmon (synthetic origin) Nasal Spray is ready for you to use. Do not prime the pump before you use it each day because this will waste your medicine. Giving your Calcitonin Salmon (synthetic origin) Nasal Spray dose: Step 5. Insert the nasal spray pump in 1 side of your nose. See Figure 3. Keep your head upright. Carefully tilt the bottle and place the nose spray pump into 1 side of your nose. Step 6. Firmly press down on the nose spray pump to release the medicine. See Figure 4. Give 1 spray of Calcitonin Salmon (synthetic origin) Nasal Spray, 1 time daily, in 1 side of your nose (nostril). Spray your medicine in a different side of your nose each day. You do not need to breathe or inhale while you are giving your dose. You may not feel the spray inside your nose. Some of the medicine may drip out of your nose. This is normal, and you are still getting all of the medicine you need. Cleaning your Calcitonin Salmon (synthetic origin) Nasal Spray pump: Step 7. Wipe the nose spray pump with a clean, damp cloth 1 to 2 times a week. See Figure 5. Dry the nose spray pump with a clean cloth. Storing your Calcitonin Salmon (synthetic origin) Nasal Spray: Step 8. Replace the blue safety clip, then replace the protective cap on the nasal spray unit. See Figure 6 . Be careful not to push down on the pump while you are putting the cap back on it. Do not refrigerate Calcitonin Salmon (synthetic origin) Nasal Spray between doses. Store Calcitonin Salmon (synthetic origin) Nasal Spray upright. Do not shake the bottle. When should I throw away Calcitonin Salmon (synthetic origin) Nasal Spray? Unopened, refrigerated bottles can be used until the expiration date stamped on the bottle and box. Throw away Calcitonin Salmon (synthetic origin) Nasal Spray after you use 14 doses (2 mL fill) or 30 doses (3.7 mL fill) (sprays). Throw away Calcitonin Salmon (synthetic origin) Nasal Spray bottles left at room temperature (opened or unopened) for more than 30 days (2 mL fill) or 35 days (3.7 mL fill). For more information on Calcitonin Salmon (synthetic origin) Nasal Spray, call Apotex Corp. at 1-800-706-5575. This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration. APOTEX INC. CALCITONIN SALMON (SYNTHETIC ORIGIN) NASAL SPRAY Manufactured by Manufactured for Apotex Inc. Apotex Corp. Toronto, Ontario Weston, FL Canada M9L 1T9 33326 Revised: November 2017

17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information and Instructions for Use). Instruct patients on pump assembly, priming of the pump, and nasal introduction of Calcitonin Salmon (synthetic origin) Nasal Spray. Although instructions for patients are supplied with the individual bottle, procedures for use should be demonstrated to each patient [see Dosage and Administration (2.2)] . Patients should notify their healthcare provider if they develop significant nasal irritation [see Warnings and Precautions (5.3)] . Inform patients of the potential increase in risk of malignancy [see Warnings and Precautions (5.4)] . Advise patients to maintain an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day) intake [see Dosage and Administration (2.3)] . Instruct patients to seek emergency medical help or go to the nearest hospital emergency room right away if they develop any signs or symptoms of a serious allergic reaction. Advise patients how to correctly store unopened and opened product [see How Supplied/Storage and Handling (16)] . Advise patients that the bottle should be discarded after 14 doses (2 mL fill) or 30 doses (3.7 mL fill), because after 14 or 30 doses, each spray may not deliver the correct amount of medication even if the bottle is not completely empty. APOTEX INC. CALCITONIN SALMON (SYNTHETIC ORIGIN) NASAL SPRAY Manufactured by Manufactured for Apotex Inc. Apotex Corp. Toronto, Ontario Weston, FL Canada M9L 1T9 33326 Revised: November 2017

14 CLINICAL STUDIES Two randomized, placebo-controlled, two-year trials were conducted in 266 postmenopausal women who were greater than 5 years postmenopause with spinal, forearm or femoral bone mineral density (BMD) at least one standard deviation below the normal value for healthy premenopausal women (T-score < -1). In both studies, a total of 144 patients received calcitonin salmon nasal spray 200 International Units or placebo daily. The intent-to-treat population comprised 139 patients who had at least one follow-up BMD measurement. In study 1, patients also received 500 mg daily calcium supplements, while in study 2, patients received no calcium supplementation. The primary endpoint for both studies was percent change in lumbar spine BMD at 2 years. Calcitonin salmon nasal spray increased lumbar vertebral BMD relative to placebo in women with low bone mass who were greater than 5 years post menopause (see Table 3 below). Table 3: Calcitonin Salmon Nasal Spray: Lumbar Spine Bone Mineral Density In Women Greater Than 5 years Postmenopause With Low Bone Mass ITT: Intent To Treat IU: International Units NS: nasal spray †p-values by parametric testing (2-tailed 2-sample t-test) Lumbar Spine Bone Mineral Density, Mean Change From Baseline (in %) at Month 24 Study 1 (with calcium supplement) n (ITT) = 100 Study 2 (no calcium supplement) n (ITT) = 39 Calcitonin Salmon 200 IU NS daily +1.56 +1.02 Placebo +0.20 -1.85 Treatment Difference +1.36 +2.87 p-value† < 0.05 < 0.005 No effects of calcitonin salmon nasal spray on cortical bone of the forearm or hip were demonstrated. In clinical studies of postmenopausal osteoporosis, bone biopsy and radial bone mass assessments at baseline and after 26 months of daily injectable calcitonin salmon indicate that calcitonin therapy results in the formation of normal bone.

8.5 Geriatric Use In a multi-centered, double-blind, randomized clinical study of calcitonin salmon nasal spray, 279 patients were less than 65 years old, while 467 patients were 65 to 74 years old and 196 patients were 75 years old and older. Compared to subjects less than 65 years old, the incidence of nasal adverse reactions (rhinitis, irritation, erythema, and excoriation) was higher in patients over the age of 65, particularly among those over the age of 75. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.1 Pregnancy Risk Summary Calcitonin salmon nasal spray is not indicated for use in females of reproductive potential. There are no data with the use of calcitonin salmon nasal spray in pregnant women. In an animal reproduction study, subcutaneous administration of calcitonin-salmon to pregnant rabbits during organogenesis at 418 times the recommended parenteral human dose caused a decrease in fetal birth weights. No adverse developmental outcome was observed in the rat with subcutaneous administration of calcitonin-salmon at 9 times the recommended human parenteral dose based on body surface area (see Data). Data Animal Data Calcitonin salmon has been shown to cause a decrease in fetal birth weights in rabbits when given by subcutaneous injection in doses 4 to 18 times the parenteral dose (of 54 International Units/m 2 ) and 70 to 278 times the intranasal dose recommended for human use based on body surface area. No embryo/fetal toxicities related to calcitonin salmon nasal spray were reported from maternal subcutaneous daily doses in rats up to 80 International Units/kg/day from gestation day 6 to 15.

8 USE IN SPECIFIC POPULATIONS There are no data to support use in children ( 8.4 ) Nasal reactions are more common in elderly patients ( 8.5 ) 8.1 Pregnancy Risk Summary Calcitonin salmon nasal spray is not indicated for use in females of reproductive potential. There are no data with the use of calcitonin salmon nasal spray in pregnant women. In an animal reproduction study, subcutaneous administration of calcitonin-salmon to pregnant rabbits during organogenesis at 418 times the recommended parenteral human dose caused a decrease in fetal birth weights. No adverse developmental outcome was observed in the rat with subcutaneous administration of calcitonin-salmon at 9 times the recommended human parenteral dose based on body surface area (see Data). Data Animal Data Calcitonin salmon has been shown to cause a decrease in fetal birth weights in rabbits when given by subcutaneous injection in doses 4 to 18 times the parenteral dose (of 54 International Units/m 2 ) and 70 to 278 times the intranasal dose recommended for human use based on body surface area. No embryo/fetal toxicities related to calcitonin salmon nasal spray were reported from maternal subcutaneous daily doses in rats up to 80 International Units/kg/day from gestation day 6 to 15. 8.2 Lactation Risk Summary Calcitonin salmon nasal spray is not indicated for use in females of reproductive potential. There is no information on the presence of calcitonin-salmon in human milk, the effects on the breastfed child, or the effects on milk production. Calcitonin has been shown to inhibit lactation in rats. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use In a multi-centered, double-blind, randomized clinical study of calcitonin salmon nasal spray, 279 patients were less than 65 years old, while 467 patients were 65 to 74 years old and 196 patients were 75 years old and older. Compared to subjects less than 65 years old, the incidence of nasal adverse reactions (rhinitis, irritation, erythema, and excoriation) was higher in patients over the age of 65, particularly among those over the age of 75. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Calcitonin Salmon (synthetic origin) Nasal Spray is available as a metered dose clear solution in a 3.7 mL fill clear glass bottle that contains 2,200 USP Calcitonin Salmon Units calcitonin salmon per mL. A pump is attached to the bottle.After priming, the pump will deliver 200 USP Calcitonin Salmon Units per activation (0.09 mL per spray). NDC: 72162-2128-03: 3.7 mL (30 doses) in a BOTTLE, GLASS Storage and Handling Store unopened bottle in refrigerator between 2°C to 8°C (36°F to 46°F). Protect from freezing. Store bottle in use at room temperature between 20°C to 25°C (68°F to 77°F) in an upright position, for up to 35 days (3.7 mL fill). Each bottle contains at least 30 doses (3.7 mL fill). Discard bottle after 30 doses (3.7 mL fill). Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504